Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation.

Abstract

Pharmacological data and early clinical experience have suggested that the calcium entry blocker flunarizine may be a valuable gain in the prophylaxis of migraine. This was supported by a study in 20 patients with classical migraine who were, after a drug free run-in phase, orally treated with either placebo or flunarizine (10 mg at night) for 3 to 4 months. Flunarizine significantly reduced the frequency, duration and severity of the migraine attacks. A corrected migraine index, based on these 3 variables was reduced by 82% in the drug group but increased by 66% in the control patients. Only 1 patient did not clearly benefit from flunarizine. In some cases flunarizine should be administered for at least 4 months before judging its efficacy. No side-effects occurred.

• Authors: G Mendenopoulos, T Manafi, I Logothetis, S Bostantjopoulou
• Journal: Cephalalgia : an international journal of headache (Cephalalgia) Vol. 5 Issue 1 Pg. 31-7 (Mar 1985) ISSN: 0333-1024 [Print] England
• PMID: 3886152 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Calcium Channel Blockers
• Piperazines
• Placebos
• Cinnarizine
• Flunarizine

Topics

• Adult
• Aged
• Calcium Channel Blockers (adverse effects, therapeutic use)
• Cinnarizine (adverse effects, analogs & derivatives, therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Flunarizine
• Humans
• Male
• Middle Aged
• Migraine Disorders (prevention & control)
• Piperazines (therapeutic use)
• Placebos